Skip to content
OpenCapital
Get started

Avalo Therapeutics AVTX Q3 2025 earnings

Reported November 6, 2025 · Before market open

Revenue-Diluted EPS-$2.19Miss by $0.52
EPS estimate-$1.67

Next report

Aug 6, 2026 (In 3 weeks)
EPS estimate-$0.66

Financials

Q3 2025

Income statement

See full
Revenue--100%
Operating income-$19.2M-49.3%
Net income-$30.6M-233%
EPS (diluted)-$2.19+22.6%

Balance sheet

See full
Cash & equivalents$27.3M-66.8%
Total debt$555.0K-66.0%
Total equity$91.5M+334%
Total assets$125.1M+27.1%

Cash flow

See full
Operating cash flow-$16.4M-42.0%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$167.17M+81.4%
Enterprise value$140.46M+1,095%

Returns & leverage

See full
Return on equity-177.4%-267pp
Debt / equity0×-0.1×
Current ratio14.3×+12.9×

Versus estimates

Revenue

Q4 2025$59.0KIn lineQ4 2024$192.0K

Diluted EPS

Q1 2026-$0.98Beat by $0.02Q4 2025-$0.37Beat by $1.17
Q3 2025-$2.19Miss by $0.52
Q2 2025-$1.92Miss by $0.49Q1 2025-$1.25Miss by $0.18Q4 2024-$7.95Miss by $8.53

Ask the moment Avalo Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Avalo Therapeutics report Q3 2025 earnings?
Avalo Therapeutics (AVTX) reported Q3 2025 earnings on November 6, 2025 before market open.
What were Avalo Therapeutics's Q3 2025 revenue and EPS?
Avalo Therapeutics reported revenue of - and diluted EPS of $-2.19 for Q3 2025.
Did Avalo Therapeutics beat estimates in Q3 2025?
EPS missed the consensus estimate of $-1.67 by $0.52.
How did Avalo Therapeutics's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 100.0% from $249.0K a year earlier and diluted EPS grew 22.6% from $-2.83.
Where can I find Avalo Therapeutics's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001534120-25-000017) and the 10-Q periodic report (0001534120-25-000018) directly on SEC EDGAR. The filing index links above go to sec.gov.